Image Removed
Image Added
Project Scope |
Cloud technology and its use of multi-tennant app solutions are increasing the capabilities of Life Sciences solutions and reducing IT infrastructure costs through the sharing of infrastructure and investment cross-industry. In some areas multi-tenant cloud solutions have become ubiquitous. For example, Salesforce.com claim >150K customers utilize their platform for Customer Relationship Management. Furthermore, many routinely rely on cloud Cloud services associated with their computer backups and data services associated with cell phones. Nonetheless, the perceptions and interpretations of the regulations by which the life sciences Life Sciences industry must conduct its business still leave many uncertain about whether or not they can - (or should - ) pursue the use of cloud Cloud solutions for GxP applications. The goal of this work stream project has been to provide a practical, usable framework to overcome those barriers. Through the use of this framework, it is envisaged that the barriers to adoption by pharma Pharma of cloudCloud-based technology will be addressesaddressed. |
Project Leads | Email |
---|
Anders Vidstrup |
avid@nnit.com | Wendy Dobson (PHUSE Project Manager) | wendy@phuse.global |
Deliverables | Timelines |
---|
Finalise Chapters and send for internal review | Q12021 |
Publish final framework | Q12021
Status |
---|
colour | Blue |
---|
title | Current Status |
---|
|
|
---|
Q42021Draft of 2 appendix ongoing and will be shared with project members for feedback in by end of AprilWill consolidate and then update the appendix |
---|
- Complete Cloud Framework document.
|
The team has representatives from SaaS, PaaS and IaaS providers, as well as 'consumer organisations' Stakeholders. This |
workstream project has generated value for several levels of stakeholders. |
- cloud - , it has generated use cases that illustrate the successful implementations, or pitfalls, in the use of
|
cloud cloud Cloud technologies as well as providing decision trees to support technology decision making. For the regulatory professionals, it provides a clear mapping between technology capabilities and regulatory requirements
|
Resources
Objectives & Deliverables | Timelines |
---|
Updated main document - Preamble | Q3 2022 |
- , 24-Apr-2019 Pre AmbleCloud Webinar Nov18pdfProject Members | Company |
---|
Anupama Sheoran | Bayer |
Bob Streit | Janssen Research & Development |
Catherine Li | FDA |
Chris Whalley | Industry |
Dan Dziadiw | Merck, Sharp & Dohme |
Evi Cohen | Appian |
Eunice Ndungu | Merck, Sharp & Dohme |
Hans Peter-Schreiter | Entimo |
Lynn Caldwell | Pfizer |
Martijn Van Beelen | GSK |
Andrew Matteson | Applied Biomath |
Pieter Stas | Business & Decision Life Science |
Raechelle Raimondo | Allergan |
Richard Martinez | RHO World |
Rocco Timpano | Pfizer |
Sandy Estrada | Cervello |
Serena Pierson | Accenture |
Stuart Ward | IDBS |
Suzanne Studinger | QAS AG |
William Telford | Sanofi